logo
Plus   Neg
Share
Email

Vaxart Joins With Emergent To Advance Experimental COVID-19 Vaccine

Emergent BioSolutions Inc. (EBS) has entered into an agreement with Vaxart, Inc. (VXRT), under which Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart's experimental oral vaccine candidate for COVID-19. Emergent agreed to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020.

Emergent will provide development services out of its Gaithersburg, Md. location and manufacture drug substance at its Bayview facility in Baltimore, Md.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT